[1]马瑜宏,张延荃,孙莲芳.宽带汤联合西药对慢性盆腔炎患者HMGB-1、sRAGE和TLR-4通路的影响[J].西部中医药,2020,33(07):125-128.[doi:10.12174/j.issn.1004-6852.2020.07.33]
 MA Yuhong,ZHANG Yanquan,SUN Lianfang.Effects of Kuandai Tang Combined with Western Medicine on HMGB-1, sRAGE and TLR-4 Pathway in CPID Patients[J].Western Journal of Traditional Chinese Medicine,2020,33(07):125-128.[doi:10.12174/j.issn.1004-6852.2020.07.33]
点击复制

宽带汤联合西药对慢性盆腔炎患者HMGB-1、sRAGE和TLR-4通路的影响
分享到:

《西部中医药》[ISSN:1006-6977/CN:61-1281/TN]

卷:
33
期数:
2020年07期
页码:
125-128
栏目:
报道·衷中参西
出版日期:
2020-07-15

文章信息/Info

Title:
Effects of Kuandai Tang Combined with Western Medicine on HMGB-1, sRAGE and TLR-4 Pathway in CPID Patients
文章编号:
1004-6852(2020)07-0125-04
作者:
马瑜宏张延荃孙莲芳
上海市岳阳中西医结合医院闵行分院妇产科,上海 200241
Author(s):
MA Yuhong ZHANG Yanquan SUN Lianfang
Department of Obstetrics and Gynecology, Minhang Branch of Shanghai Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai 200241, China
关键词:
慢性盆腔炎高迁移率族蛋白B1可溶性晚期糖基化终末产物受体Toll样受体-4宽带汤中西医结合
Keywords:
CPID HMGB-1 sRAGE TLR-4 Kuandai Tang integrative medicine
分类号:
R711.33
DOI:
10.12174/j.issn.1004-6852.2020.07.33
文献标志码:
B
摘要:
目的:观察宽带汤联合西药治疗慢性盆腔炎的疗效及其对高迁移率族蛋白B1(high mobility group protein B1,HMGB-1)、可溶性晚期糖基化终末产物受体(soluble advanced glycation end product receptor,sRAGE)和Toll样受体-4(toll like receptor-4,TLR-4)通路的影响。方法:将慢性盆腔炎患者104例按照随机数字表法分为观察组和对照组各52例。对照组予常规抗炎治疗,观察组在对照组基础上予宽带汤治疗。观察两组患者治疗后疗效和复发率,观察两组患者治疗前后中医证候积分、平均月经量、平均月经经期、疼痛视觉模拟评分(visual analogue scale,VAS),观察两组患者全血高切、低切黏度,血细胞比容、红细胞沉降率及HMGB-1、sRAGE和TLR-4水平。结果:总有效率观察组为94.2%(49/52),高于对照组的76.9%(40/52),差异有统计学意义( χ2=4.986,P<0.05)。复发率观察组为1.9%(1/52),低于对照组的15.4%(8/52)( χ2=4.379,P<0.05)。治疗后两组患者全血高切、低切黏度及血细胞比容、红细胞沉降率均较治疗前下降,观察组低于对照组(P<0.01)。治疗后两组患者中医证候积分、平均月经量、平均月经经期,VAS评分,HMGB-1和TLR-4水平均较治疗前降低(P<0.01),sRAGE水平较治疗前升高(P<0.01),观察组降低或升高较对照组明显(P<0.01)。结论:宽带汤联合西药治疗慢性盆腔炎疗效优于单纯西药治疗,且复发率低,其机制可能与通过HMGB-1、sRAGE和TLR-4通路减轻炎症反应有关。
Abstract:
Objective: To observe clinical effects of Kuandai Tang combined with Western medicine in the treatment of chronic pelvic inflammatory disease(CPID) and its impacts on the high mobility group protein B1 (HMGB-1), soluble advanced glycation end product receptor(sRAGE) and Toll-like receptor-4(TLR-4) pathway. Methods: A total of 104 patients were allocated to the observation group and the control group using random number table method, 52 cases each group. The control group accepted conventional anti-inflammation therapy, and the observation group were given Kuandai Tang. To observe clinical effects, the relapse rate between both groups after treating, to detect TCM syndrome scores, mean menstrual volume, average menstrual period, VAS scores before and after treating, to investigate the values of whole blood high shear viscosity, low shear viscosity, hematocrit (HCT), erythrocyte sedimentation rate (ESR), the levels of HMGB-1, sRAGE and TLR-4. Results: Total effective rate of the observation group was 94.2%(49/52), higher than 76.9%(40/52) of the control group, and the difference had statistical meaning ( χ2=4.986, P<0.05). The relapse rate of the observation group was 1.9%(1/52), lower than 15.4% (8/52)of the control group( χ2=4.379, P<0.05). After treating, the values of whole blood high shear viscosity, low shear viscosity, HCT and ESR of both groups were lower than before treating (P<0.01). After treating, TCM syndrome scores, mean menstrual volume, average menstrual period, VAS scores, the levels of HMGB-1 and TLR-4 of both groups reduced compared with these before treating(P<0.01), while the levels of sRAGE rose than before treating(P<0.01), the decrease or the improvements of the observation group were more notable than these of the control group(P<0.01). Conclusion: Kuandai Tang combined with Western medicine are superior to only Western medicine in the treatment of CPID, it shows low relapse rate, and its mechanism might be related to impoving the inflammation of CPID via HMGB-1, sRAGE and TLR-4 pathway.

相似文献/References:

[1]黄叶芳,袁野,陆华△.花红胶囊及花红颗粒治疗慢性盆腔炎(湿热瘀结证)的临床观察[J].西部中医药,2013,26(02):4.
 HUANG Yefang,YUAN Ye,LU Hua.Clinical Observation on HuaHong Capsule and HuaHong Granules in Treating Chronic Pelvic Inflammatory Disease of Dampness-heat Accumulation Pattern[J].Western Journal of Traditional Chinese Medicine,2013,26(07):4.
[2]田凌,张岩雪,王翔燕,等.丹莪活血清热组方联合蒸热疗法治疗慢性盆腔炎临床疗效观察*[J].西部中医药,2013,26(10):104.
 TIAN Ling,ZHANG Yanxue,WANG Xiangyan,et al.Clinical Effects of DanE Blood-activating Heat-clearing Prescription and Steaming Therapy for Chronic Pelvic Inflammation[J].Western Journal of Traditional Chinese Medicine,2013,26(07):104.
[3]马春瑜.少腹逐瘀汤治疗慢性盆腔炎的临床观察[J].西部中医药,2014,27(07):89.
 MA Chunyu.Clinical Observation on ShaoFu ZhuYu Decoction in Treating Chronic Pelvic Inflammatory Disease[J].Western Journal of Traditional Chinese Medicine,2014,27(07):89.
[4]刘清,邓翀△,黄淑凤,等.大血藤对慢性盆腔炎模型大鼠血清IL-6、TNF-α及子宫病理组织形态学的影响[J].西部中医药,2016,29(07):11.
 LIU Qing,DENG Chong,HUANG Shufeng,et al.Influence of DaXueTeng on Pathological Morphology, IL-6 and TNF-α of the Rats with Chronic Pelvic Inflammatory Disease[J].Western Journal of Traditional Chinese Medicine,2016,29(07):11.
[5]缪绿妍,杨艳琳,吴艳春,等.基于网络药理学结合彩超图像研究临床经验方盆炎合剂的作用机制[J].西部中医药,2019,32(02):37.
 MIU Lyuyan,YANG Yanlin,WU Yanchun,et al.Study on the Mechanism of Clinical Empirical Prescription PenYan Mixture Based on Network Pharmacology and Color Ultrasound Image[J].Western Journal of Traditional Chinese Medicine,2019,32(07):37.

备注/Memo

备注/Memo:
收稿日期:2019-05-20作者简介::马瑜宏(1980—),女,主治医师。研究方向:慢性盆腔炎的诊断与治疗。
更新日期/Last Update: 2020-07-15